Press releases and news
2024
Camurus’ Nomination Committee appointed for the Annual General Meeting 2025
Camurus to present at Jefferies London Healthcare Conference
Camurus’ Interim Report Third Quarter 2024
Camurus improves ESG rating score by MSCI
Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly
Change in number of shares and votes in Camurus
EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease
Exercise in Camurus’ employee stock options program 2021/2024
Camurus recognized in Fortune’s Top 25 “Leading the charge: Spotlighting the 25 companies smashing the glass ceiling”
Camurus’ Interim Report Second Quarter 2024
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Change in number of shares and votes in Camurus
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Camurus submits its first UN Global Compact Communication on Progress and renews the Nasdaq Transparency Partner certificate
Exercise of Camurus’ employee stock options program 2021/2024
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027
Camurus to present at Jefferies 2024 Healthcare Conference New York
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
Resolutions at the annual general meeting 2024 in Camurus
Camurus’ Interim Report January-March 2024
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.